Long-acting insulin analogs versus neutral protamine hagedorn insulin and the risk of severe hypoglycemia among patients in type 2 diabetes in the United Kingdom

被引：0
|
作者：
Brunetti, Vanessa C. [1 ]
Filion, Kristian [2 ]
Yu, Oriana Hoi Yun [2 ]
Platt, Robert [2 ]
机构：
[1] McGill, Dept Epidemiol Biostatist & Occupat Hlth, Montreal, PQ, Canada
[2] McGill Univ, Montreal, PQ, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2022年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
267
引用
收藏
页码：114 / 114
页数：1
相关论文
共 50 条
  • [41] Intermediate-acting versus long-acting insulin for type 1 diabetes mellitus
    不详
    JOURNAL OF DIABETES, 2009, 1 (03) : 138 - 138
  • [42] Long-acting insulin analogues versus NPH human insulin in type 2 diabetes - A meta-analysis
    Monami, Matteo
    Marchionni, Niccolo
    Mannucci, Edoardo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 81 (02) : 184 - 189
  • [43] Long-acting insulin analogues versus human isophane insulin for type 2 diabetes: update of a Cochrane review
    Engler, J.
    Horvath, K.
    Semlitsch, T.
    Jeitler, K.
    Berghold, A.
    Siebenhofer, A.
    DIABETOLOGIA, 2018, 61 : S409 - S410
  • [44] Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes
    Schmid, C.
    Krayenbuhl, P.
    Wiesli, P.
    DIABETOLOGIA, 2009, 52 (12) : 2668 - 2669
  • [45] Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naive people with type 2 diabetes
    Home, P. D.
    Bolli, G. B.
    Mathieu, C.
    Deerochanawong, C.
    Landgraf, W.
    Candelas, C.
    Pilorget, V.
    Dain, M. -P.
    Riddle, M. C.
    DIABETES OBESITY & METABOLISM, 2015, 17 (01): : 15 - 22
  • [46] Increased insulin dose requirement of long-acting insulin analogues in obese patients with type 2 diabetes
    C. Schmid
    P. Krayenbühl
    P. Wiesli
    Diabetologia, 2009, 52 : 2668 - 2669
  • [47] Effects of Long Acting Insulin Versus Rapid Acting Insulin on Oxidative Stress in Patients with Type 2 Diabetes
    Naruse, Rika
    Takebayashi, Kohzo
    Aso, Yoshimasa
    Inukai, Toshihiko
    DIABETES, 2011, 60 : A291 - A291
  • [48] Insulin therapy in type 2 diabetes:: role of the long-acting insulin glargine analogue
    Yki-Järvinen, H
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (06) : 410 - 416
  • [49] The Use of Long-Acting Insulin Analogues and the Risk of Colorectal Cancer in Patients with Type 2 Diabetes Mellitus
    Pradhan, Richeek
    Yin, Hui
    Yu, Oriana HoiYun
    Azoulay, Laurent
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 52 - 52
  • [50] A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus
    Min Liu
    Zhiguang Zhou
    Jinhua Yan
    Pin Li
    Wenhui Song
    Junfen Fu
    Xiaobo Chen
    Weigang Zhao
    Li Xi
    Xiaoping Luo
    Liang Sha
    Xueyuan Deng
    Chunxiu Gong
    BMC Endocrine Disorders, 16
12345